Figures & data
Table 1 Pooled population demographics and baseline characteristics of patients in the GEM1 and GEM2 studies by bronchodilator reversibility (FAS)
Figure 1 LSM change from baseline in (A) FEV1 AUC0–12 h and (B) trough FEV1 at week 12 by bronchodilator reversibility status (FAS).
Abbreviations: AUC0–12 h, area under the curve from 0 to 12 hours; BID, twice daily; FAS, full analysis set; GLY, glycopyrrolate; LSM, least squares mean; SE, standard error.
Figure 2 LSM change from baseline in (A) SGRQ and (B) CAT total scores at week 12 by bronchodilator reversibility status (FAS).
Abbreviations: BID, twice daily; CAT, COPD assessment test; FAS, full analysis set; GLY, glycopyrrolate; LSM, least squares mean; SE, standard error; SGRQ, St George’s Respiratory Questionnaire.
Figure 3 LSM TDI focal score at week 12 by bronchodilator reversibility status (FAS).
Abbreviations: BID, twice daily; FAS, full analysis set; GLY, glycopyrrolate; LSM, least squares mean; SE, standard error; TDI, Transition Dyspnea Index.
Figure 4 Pooled analysis of mean total (A) daily, (B) daytime, and (C) nighttime symptom scores over 12 weeks by bronchodilator reversibility status (FAS). Notes: *P<0.05; **P<0.01 vs placebo.
Figure 5 Pooled analysis of change from baseline in (A) daily, (B) daytime, (C) nighttime rescue medication use, and (D) days with no rescue medication use over 12 weeks of treatment by bronchodilator reversibility status (FAS).
Abbreviations: BID, twice daily; FAS, full analysis set; GLY, glycopyrrolate; LSM, least squares mean; SE, standard error.
Table 2 Pooled analysis of the most common AEsTable Footnotea by bronchodilator reversibility (safety population)
Table S1 LSM change from baseline in trough FEV1 (L) by reversibility status and ICS use at baseline (FAS)